In an era of increasingly complex global supply chains and heightened regulatory scrutiny following the COVID-19 pandemic, the pharmaceutical industry faces a critical challenge: how to move from reactive crisis management to proactive supply reliability. While regulatory bodies worldwide have launched numerous initiatives to prevent shortages, industry efforts are also driving real-world...

How do you validate cleaning processes for ADCs, monoclonal antibodies (mAbs), and highly potent active pharmaceutical ingredients (HPAPIs)? What role do degradation studies, cleaning-agent selection, and analytical testing play in reducing validation risk and supporting regulatory expectations?

Pharmaceutical manufacturing depends on precision, rigor, and compliance. But technical excellence alone does not keep operations moving. Engineers, quality professionals, production teams, scientists, and regulatory personnel must continually exchange technical information, make decisions, and align around shared priorities.

A biologic drug product compounding step often transfers seamlessly on paper. The formulation is unchanged, the order of addition is the same, and the target concentration remains identical. The batch record at the receiving site calls for the qualified mixing speed and mixing time, and that is what the operator follows. Everything appears to match.

As biomanufacturing campuses grow in scale and complexity, organizations need facility strategies that can support rapid expansion, regulatory compliance, and long-term operational resilience. This blog post examines the role of architect-led campus master planning in aligning product pipeline assumptions, manufacturing requirements, technical infrastructure, logistics, and implementation...

US Food and Drug Administration (US FDA) investigators do not start with the deviation log. They start somewhere else. Most facilities do not know where.

How can pharmaceutical companies achieve inspection-ready digital compliance in the Pharma 4.0™ era? As manufacturers adopt artificial intelligence (AI), connected manufacturing systems, advanced analytics, cloud platforms, and digital quality processes, regulatory compliance must be built into operations from the beginning rather than addressed after implementation....

The ISPE Foundation Professional Development Grant program is designed to help students and recent graduates accelerate their professional growth by participating in premier industry events. Through financial support to attend ISPE conferences, the program provides emerging professionals with opportunities to learn from industry experts, explore the latest trends shaping pharmaceutical...

Driven by a passion for science, problem-solving, and improving patient outcomes, Keira Mull is building a career in pharmaceutical manufacturing centered on continuous improvement and service. As a Senior Manufacturing Specialist at AstraZeneca and an active volunteer with ISPE's Chesapeake Bay Area Chapter, she is committed to operational excellence, mentorship, and professional...

FUJIFILM Biotechnologies’ Galaxy project is redefining how large-scale biopharmaceutical manufacturing facilities are designed, built, and deployed. Recognized with an Honorable Mention in the 2026 ISPE Facility of the Year Awards (FOYA), the facility exemplifies how digital replication, modular construction, and Pharma 4.0™ technologies can accelerate the delivery of critical manufacturing...

This past June at the 2026 ISPE AI in Life Sciences Summit – Powered by GAMP®, I spent time with professionals from across our industry discussing AI, emerging technologies, and what comes next for pharmaceutical manufacturing. Those conversations prompted me to reflect on a topic that was woven throughout the event: innovation and how it happens.

Quality and regulatory teams face a constant stream of external signals: draft and final guidance, inspection trends, revised standards, pharmacopeial updates, and industry commentary. Monitoring these signals is routine; deciding what to do with them is not. The common practice for most companies is to disseminate information broadly regarding updates but apply differing levels of scrutiny...